Page 238 - Drug Class Review
P. 238
Page 149 of 205
Drug Effectiveness Review Project
Groups similar at baseline: No; significantly more females randomized to DON
donepezil 72.8 68.2 98.9 14.8 Secondary Outcome Measures: MMSE; ADAS-Cog 11; NPI; SCGB BADLS scores showed no significant difference between treatment groups in mean change from Changes from baseline in NPI similar for both treatments At endpoint, a higher percentage of GAL than DON patients reported maintenance or improvement of objective and subjective caregiver burden (SCGB); 67.1% and 68.3% respectively for GAL, and 51.3% and 49.4% respectively for DON; significance NR GAL patients showed no significant improvement in MMSE scores (P > 0.05), whereas DON patient
Alzheimer classification: Mild-moderate-severe
Health Outcome Measures: DON
galantamine 74.1 56.4 100 15.1 Primary Outcome Measures: BADLS Timing of assessments: Baseline and weeks 13, 26 and 52 baseline to week 52 Intermediate Outcome Measures: between group differences in MMSE not significant
• • • • •
Final Report Update 1 Authors: Wilcock et al. Year: 2003 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% white): Other germane population qualities: Mean screening MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
